SHR-8068 + adebrelimab + oxaliplatin + capecitabine + paclitaxel + cisplatin

This is a combination regimen consisting of six agents used in clinical trials for the treatment of advanced gastric and esophageal cancers, as well as other solid tumors. The components are: - **SHR-8068**: A monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), acting as an immune checkpoint inhibitor to enhance antitumor immune responses[1][2][3][4]. - **Adebrelimab**: A high-affinity, humanized IgG4 monoclonal antibody against programmed death-ligand 1 (PD-L1), also functioning as an immune checkpoint inhibitor to promote T-cell-mediated antitumor activity[3][6]. - **Oxaliplatin**: A platinum-based chemotherapeutic agent that forms DNA crosslinks, inhibiting DNA replication and transcription in cancer cells[7]. - **Capecitabine**: An oral prodrug converted to 5-fluorouracil (5-FU) in the body, which inhibits thymidylate synthase and disrupts DNA synthesis in rapidly dividing cells[7]. - **Paclitaxel**: A microtubule-stabilizing agent that inhibits cell division by preventing microtubule depolymerization. - **Cisplatin**: Another platinum-based chemotherapy drug that causes DNA crosslinking and apoptosis in cancer cells. This combination is being investigated primarily for unresectable or metastatic adenocarcinoma of the stomach or gastroesophageal junction, and esophageal squamous cell carcinoma. The regimen leverages both immunotherapy (immune checkpoint blockade) and cytotoxic chemotherapy for synergistic antitumor effects[5].